SCHEMBL3569155

SCHEMBL3569155

CC(C)(C)C(=O)N1CCC(C(=O)CBr)(c2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 1/20 0.50
OPRD1 P41143 4/20 0.47
SLC18A3 Q16572 1/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
TET3 O43151 1/20 0.44
FBXL19 Q6PCT2 1/20 0.44
CXXC5 Q7LFL8 1/20 0.44
TET1 Q8NFU7 1/20 0.44
KDM2B Q8NHM5 1/20 0.44
CXXC4 Q9H2H0 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
HSD11B1 P28845 2/20 0.42
OPRM1 P35372 5/20 0.42
OPRK1 P41145 3/20 0.42
SLC22A1 O15245 1/20 0.42
SLC6A4 P31645 1/20 0.42
ADRA1A P35348 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543988 0.83 CA12 (0.54) CCR5OPRD1KMT2AMEN1TET3
SCHEMBL19207553 0.79 AKR1C1 (0.52) SLC18A3KMT2AMEN1HTTHSD11B1
SCHEMBL27099796 0.77 MEN1 (0.51) CCR5OPRD1KMT2AMEN1ALDH1A1
SCHEMBL18701601 0.77 MEN1 (0.51) OPRD1KMT2AMEN1ALDH1A1HTT
SCHEMBL18701649 0.76 SCD5 (0.53) OPRD1KMT2AMEN1ALDH1A1HTT
SCHEMBL16507538 0.76 AKR1C1 (0.58) SLC18A3KMT2AMEN1ALDH1A1HTT
SCHEMBL1309812 0.73 SLC18A3 (0.60) OPRD1SLC18A3KMT2ATET3FBXL19
SCHEMBL18701791 0.72 CA12 (0.58) OPRD1KMT2AMEN1OPRM1
SCHEMBL4630029 0.72 OPRM1 (0.57) SLC18A3HTTHSD11B1OPRM1
SCHEMBL16886308 0.71 KMT2A (0.52) OPRD1KMT2AMEN1TET3FBXL19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 CCR5 1/4885OPRD1 82/4885SLC18A3 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.